Live Breaking News & Updates on Riccardo Lencioni

Stay updated with breaking news from Riccardo lencioni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Durvalumab and Bevacizumab Plus TACE Improves PFS in Embolization-Eligible, Unresectable HCC

PFS was significantly improved with durvalumab plus bevacizumab and TACE vs TACE alone in patients with unresectable HCC eligible for embolization. ....

Italy , Japan , Riccardo-lencioni , Department-of-surgery , Critical-area-pathology , Druvalumab-and-bevacizumab-plus-tace , Dotace , Hcc , Hepatocellular-carcinoma , Gastrointestinal-cancer , Gi-cancer , Asco-gi

EMERALD-1: Durvalumab and Bevacizumab Plus TACE Improves PFS in Patients With Unresectable HCC

One expert said the results have the potential to change the standard of care for some patients with the most common type of liver cancer. ....

Italy , California , United-states , San-francisco , Barcelona , Comunidad-autonoma-de-cataluna , Spain , American , Riccardo-lencioni , Cathy-eng , Division-of-hematology , Department-of-medicine

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer

AstraZeneca shares positive phase 3 results for Imfinzi combination in liver cancer
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Japan , Susan-galbraith , Riccardo-lencioni , Genentech-avastin , Astrazeneca ,

Durvalumab regimen extends PFS in certain patients with liver cancer

Durvalumab regimen extends PFS in certain patients with liver cancer
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Italy , Bymatthew-shinkle , Mindy-valcarcel , Riccardo-lencioni , Pisa-university-hospital , Genentech , Astrazeneca ,

Durvalumab Plus TACE and Bevacizumab Significantly Improves PFS in Select HCC

Durvalumab plus concurrent transarterial chemoembolization followed by durvalumab with bevacizumab resulted in a significant improvement in PFS over TACE alone in patients with hepatocellular carcinoma who are eligible for embolization, meeting the primary end point of the phase 3 EMERALD-1 trial. ....

Sangro , Italy-general , Italy , Riccardo-lencioni , Susan-galbraith , Durvalumab-imfinzi , International-liver-cancer-association-virtual-conference , Cancer-imaging-program , Astrazeneca , Interventional-radiology , Pisa-university-hospital , Liver-cancer-association-virtual-conference